Putnam BioRevolution ETF (SYNB)

Assets	$4.67M
Expense Ratio	0.70%
PE Ratio	27.21
Shares Out	150,000
Dividend (ttm)	$0.21
Dividend Yield	0.69%
Ex-Dividend Date	Dec 5, 2024
Payout Frequency	Annual
Payout Ratio	18.73%

Volume	n/a
Open	31.08
Previous Close	30.86
Day's Range	31.08 - 31.08
52-Week Low	24.57
52-Week High	31.90
Beta	0.93
Holdings	34
Inception Date	Sep 29, 2022

About SYNB

Fund Home Page

The Putnam BioRevolution ETF (SYNB) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund actively invests in companies of all sizes around the globe that enable biological innovation. SYNB was launched on Sep 29, 2022 and is issued by Putnam.

• Asset Class: Equity
• Category: Health
• Stock Exchange: NYSEARCA
• Ticker Symbol: SYNB
• ETF Provider: Putnam

Top 10 Holdings

51.37% of assets

Name	Symbol	Weight
Thermo Fisher Scientific Inc.	TMO	9.05%
AbbVie Inc.	ABBV	5.65%
NVIDIA Corporation	NVDA	5.18%
Corteva, Inc.	CTVA	4.94%
Ascendis Pharma A/S	ASND	4.77%
Novozymes A/S	NVZMY	4.62%
Bio-Rad Laboratories, Inc.	BIO	4.58%
AstraZeneca PLC	AZN	4.48%
Putnam Government Money Market Fund Class P	PGLXX	4.23%
Eli Lilly and Company	LLY	3.88%

Dividends

Ex-Dividend	Amount	Pay Date
Dec 5, 2024	$0.2139	Dec 9, 2024
Dec 6, 2023	$0.0211	Dec 11, 2023

Performance

SYNB had a total return of -1.49% in the past year, including dividends. Since the fund's inception, the average annual return has been 7.86%.